Neurotech International Limited Overview
Neurotech International is a micro-capitalisation, single-asset, clinical-stage biopharmaceutical company focused on paediatric neurological and neurodevelopmental disorders. Its sole development asset, NTI164, is a proprietary, GMP-grade, multi-constituent oral cannabinoid formulation rich in cannabidiolic acid (CBDA) with select minor cannabinoids and very low THC (0.08% per the Rett publication title), positioned on a neuroinflammation and immune-dysregulation mechanism rather than as a conventional CBD product. After completing a 54-patient Phase II/III study (HARMONY) in Autism Spectrum Disorder (ASD) and open-label Phase I/II studies in Rett syndrome and PANDAS/PANS, the company dosed its first patient in the pivotal Phase 3 "Beyond Harmony" ASD trial in September 2026 across six Australian sites. It holds US FDA IND clearance, US Orphan Drug and Rare Pediatric Disease Designations in Rett syndrome, and an EU orphan designation. Neurotech generates no product revenue, relies on R&D tax incentives and equity, and its value is almost wholly contingent on Phase 3 success and partnering.
Company's own description (FY2026 Annual Report, Principal Activities, paraphrased). Neurotech describes itself as a clinical-stage biopharmaceutical development company concentrated mainly on paediatric neurological disorders, built around a broad-spectrum oral cannabinoid drug therapy, NTI164. It highlights completion of a randomised, double-blind, placebo-controlled Phase II/III trial in ASD with statistically significant and clinically meaningful benefits across several validated measures and a favourable safety profile, completion of Phase I/II studies in ASD, PANDAS/PANS and Rett syndrome, and ethics clearance for a Phase III ASD study. The notes to the accounts additionally describe the group as a biotechnology company conducting clinical studies into the neuroprotective, anti-inflammatory and neuromodulatory activity of its proprietary cannabis strains.
Independent characterisation. Neurotech is best understood as a "virtual" drug developer: it owns intellectual property, regulatory dossiers and clinical data, while outsourcing cultivation/extraction and GMP manufacture (the FY2026 AR cites production across three Australian facilities), clinical operations (hospital sites, CROs), toxicology (GLP studies) and analytics. Its cost base is overwhelmingly clinical: of A$9.05m of FY2026 R&D expense, A$8.43m (93%) was the clinical programme. The company has no sales force, no manufacturing plant and no meaningful revenue.
Business model and revenue model.
Value-chain position. Upstream: proprietary plant genetics (historically described as "NTI/Dolce" strains) and extraction to a standardised CBDA-rich extract, produced by third-party Australian GMP facilities. Midstream: clinical development, regulatory affairs and IP. Downstream (future): either a licensed commercial partner or a self-commercialised specialty paediatric neurology product in Australia, with partner-led commercialisation more likely in the US/EU.
Customer types and end-markets. Prospective customers are paediatric neurologists, developmental paediatricians and psychiatrists treating children with moderate-to-severe (Level 2 and 3) ASD; rare-disease specialists (Rett syndrome); and paediatric immunology/neuropsychiatry clinicians (PANS/PANDAS). Current "customers" are limited to AP-program patients in Australia.
Strategy
Stated strategy (FY2026 AR themes, paraphrased). The Chairman frames FY2026 as the year Neurotech stopped being a generator of early clinical signals and became a company building a registration-grade evidence package. Strategic themes are: (1) execute the registration-enabling Beyond Harmony Phase 3 in ASD as the top priority; (2) pursue a dual TGA and FDA regulatory pathway using Australian pivotal data plus a US PopPK study; (3) broaden NTI164 into Rett syndrome, PANS and cerebral palsy on the anti-inflammatory/neuroprotective mechanism; (4) strengthen the IP estate to 2042; (5) cultivate partnering and licensing interest; (6) use the AP program for patient access and real-world evidence without treating it as a revenue line.
Initiatives in the last 24 months.
Sustainability/ESG commitments. None published beyond the corporate governance statement; the company states it is not subject to significant environmental regulation.
Cost programs. No formal programme announced; the going-concern note reserves the ability to scale back operations if funding is insufficient.
Medium-term financial targets/guidance. No revenue, earnings or margin guidance. The only quantitative guidance is that, upon completion of the August 2026 placement and with existing cash, the company expects to be funded through to topline Phase 3 readout. A topline date has not been published.
Products & Services
The company has a single active product candidate deployed across multiple indications, plus one discontinued device.
NTI164 (lead and only active asset)
| Attribute | Detail |
|---|---|
| Description | Proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids; full-spectrum plant extract with 0.08% THC per the Rett publication title |
| Proposed mechanism | Modulation of neuroinflammatory signalling, immune dysregulation, glial dysregulation and synaptic function; PANS multi-omics showed normalisation of epigenetic, ribosomal and immune pathways after treatment |
| Formulation / route | Oral; PANS study dosing 20 mg/kg/day for 12 weeks |
| Manufacturing | Third-party; production across three Australian facilities (FY2026 AR) |
| Regulatory status | FDA IND cleared (Jul 2026); FDA Orphan Drug Designation (Rett, late 2024); FDA RPDD (Rett, Oct 2025); EU Orphan Designation (by Apr 2025); Australian AP program active |
| IP | Two US applications allowed (Jul 2026) — No. 18/698,605 (methods of reducing neuroinflammation) and No. 19/335,945 (methods of treating ASD), both titled "Compositions and Methods for Treating Neurological Disorders"; expected protection to 2042 |
| Pricing | No commercial pricing; AP supply priced at cost plus modest margin (amount not disclosed) |
Indication-by-indication programme catalogue
| Programme | Indication | Phase / status | Key data or design | Target patient |
|---|---|---|---|---|
| Beyond Harmony | ASD Levels 2–3 | Phase 3, first patient dosed 21 Sep 2026; six sites (VIC, QLD, NSW, TAS, WA) | Randomised, double-blind, placebo-controlled, adaptive; primary endpoint change from baseline in Vineland-3 Adaptive Behaviour Composite; key secondaries Vineland-3 domains, SRS-2, CGI-I, CGI-S; PI Prof. Michael Fahey | Children with moderate-to-severe ASD |
| HARMONY | ASD | Phase II/III completed | 54 patients aged 2–17; statistically significant and clinically meaningful benefits across validated measures; peer-reviewed in Neurotherapeutics (2026) | As above |
| ASD Phase I/II | ASD | Completed | Safety and efficacy at 28 days, 20 and 32 weeks | Children with ASD |
| US PopPK study | ASD | Enabled by FDA IND (Jul 2026); start at company's election | Population pharmacokinetic programme to support dose characterisation and US registration | US paediatric ASD |
| Rett syndrome | Rett (MECP2) | Phase I/II open-label completed; mechanistic collaboration with University of Sydney (Feb 2026) | Published Jul 2025 in Journal of Paediatrics and Child Health: well tolerated, improvements across key symptom areas; FDA ODD + RPDD | Girls with Rett syndrome |
| PANDAS/PANS | Paediatric acute-onset neuropsychiatric syndromes | Phase I/II open-label completed | 14-child sub-cohort, 12 weeks: CGI-S improved 4.8→3.3 (p=0.002); significant improvements in anxiety, OCD, tics, ADHD symptoms and quality of life; no serious adverse events | Children with chronic relapsing PANS |
| Spastic cerebral palsy | Cerebral palsy | HREC clearance for Phase I/II (per Sep 2026 "About" statement) | Design not disclosed | Children with spastic CP |
| Authorised Prescriber Program | Range of neurodevelopmental conditions | Active since Sep 2025 | Controlled specialist-led access; generates real-world data | Australian paediatric patients |
Mente (discontinued)
| Attribute | Detail |
|---|---|
| Description | EEG-based home neurofeedback headset and software ("Mente Autism"), marketed as improving engagement and relaxation in autistic children with elevated delta-band activity |
| Launch | Late 2010s (exact year not disclosed in sources reviewed) |
| Fate | Subsidiaries placed into voluntary liquidation due to very small user numbers and no material sales (FY2025/FY2026 AR) |
Financial Narrative
Basis. FY2025 and FY2026 figures are taken from the audited FY2026 Annual Report. FY2022–FY2024 net loss and cash figures come from the companies' own Appendix 4E/annual reports (net loss FY2022 A$3,362,241; FY2023 A$7,791,939; FY2024 A$5,069,251; cash FY2022 A$1,895,431; FY2023 A$5,025,795; FY2024 A$11,625,480). Other FY2022–FY2024 line items are from StockAnalysis, Barchart, InvestSMART and Kalkine (agg.). All amounts A$000.
Income statement
Notes: Gross, operating, EBITDA and net margins are not meaningful (revenue is nil or immaterial; aggregator-computed net margins exceed −4,000,000%). Revenue CAGR is not meaningful. D&A was A$289 in FY2025 and nil in FY2026, so EBITDA ≈ operating loss. Weighted average shares: FY2025 1,035,891,510; FY2026 1,182,085,957.
Commentary. The P&L is a function of clinical intensity and the timing of R&D tax refunds. FY2023's step-up in losses reflected HARMONY enrolment; FY2024 was cushioned by a A$3.2m R&D incentive (agg.); FY2025 was the peak burn year (R&D A$9.9m plus A$1.58m non-cash share-based payments mostly tied to Fenix performance rights). FY2026's 38% reduction in net loss was driven not by lower spending (R&D only fell 9%) but by a near-doubling of the R&D refund to A$4.73m (relating to FY2025 expenditure) and a A$968k decline in share-based payments. Because the company recognises R&D grants on a cash-received basis (AR Note 1(f)), reported losses lag the underlying expenditure by roughly one year — a material quirk when comparing periods.
Balance sheet
Notes: Virtually all assets are current. Post balance date (Jul 2026) the company drew a A$3.15m secured loan from Rockford RDF against FY2026/FY2027 R&D refunds — the first debt in the five-year period. FY2026 trade payables jumped to A$2.07m (from A$0.22m), indicating Phase 3 start-up costs accrued but unpaid at year end; this stretch in payables supported reported operating cash flow.
Commentary. Equity has cycled with capital raisings: it peaked at A$11.9m in FY2024 after ~A$11m of financing inflows, then fell to A$0.61m by June 2026, equivalent to net tangible assets of 0.05 cents per share. Accumulated losses of A$58.7m against contributed equity of A$52.5m (plus a A$7.5m share-based payment reserve) show that more than the entire paid-in capital has been consumed.
Cash flow
Sources: FY2026 AR cash flow statement; FY2024 operating and financing flows per InvestSMART/Morningstar (agg., rounded); net change in cash per Barchart and reconciled to reported year-end cash.
Commentary. Gross cash burn (payments to suppliers and employees) was A$11.6m in FY2025 and A$9.0m in FY2026. Quarterly operating outflows in calendar 2026 ran at A$2.2m (Mar-2026 quarter) and A$1.9m (Jun-2026 quarter). With Phase 3 dosing now under way at six sites, burn is likely to rise; management's 4 August 2026 statement that the company is funded to topline rests on its internal budget, which has not been published in detail.
Ratios
Calculated by the analyst from the figures above; FY2022 averages use FY2021 total assets of A$5.006m and equity of ~A$3.862m (Barchart, agg.). ROIC, net debt/EBITDA, interest coverage and cash conversion cycle are not meaningful for a pre-revenue, debt-free (until Jul 2026), loss-making company. The deterioration in the current ratio to 1.29x at June 2026 is the most decision-relevant ratio: it explains the auditor's going-concern emphasis and the July–August 2026 funding actions.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Ownership | Function | Status |
|---|---|---|---|---|
Neurotech International Limited | Australia | Parent | Holds NTI164 IP, runs clinical/regulatory programme | Active |
AAT Research Ltd | Malta | 100% (direct) | Parent of AAT Medical | Being wound up (voluntary liquidation decision, Jun-2025 quarter) — still consolidated at 30 Jun 2026 |
AAT Medical Ltd | Malta | 100% (indirect) | Mente device research and development | Being wound up — still consolidated at 30 Jun 2026 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment operating revenue (AUD K) | 0 | 0.2 | 0 |
R&D tax incentive income (AUD K) | 3,180 | 2,444 | 4,734 |
Segment R&D expense (AUD K) | 5,250 | 9,942 | 9,047 |
Segment pre-tax loss (AUD K) | -5,069 | -10,599 | -6,539 |
Share of group revenue (%) | 100 | 100 | 100 |
Segment Revenue
| Category | FY2025 | FY2026 |
|---|---|---|
Product development and formulation | 395 | 321 |
Clinical programme | 9,283 | 8,433 |
Patent and IP | 264 | 172 |
Other R&D | 0 | 122 |
Total R&D expense | 9,942 | 9,047 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating revenue (AUD K) | 40 | 10 | 0 | 0.2 | 0 |
R&D tax incentive / grant income (AUD K) | 570 | 1,190 | 3,180 | 2,444 | 4,734 |
Interest income (AUD K) | 0 | 60 | 160 | 137 | 45 |
Total revenue and other income (AUD K) | 610 | 1,260 | 3,340 | 2,581 | 4,807 |
Gross profit (AUD K) | 40 | 10 | 0 | 0.2 | 0 |
R&D expense (AUD K) | 2,580 | 6,450 | 5,250 | 9,942 | 9,047 |
Share-based payments expense (AUD K) | — | — | — | 1,580 | 612 |
Employee benefits expense (AUD K) | — | — | — | 795 | 678 |
Operating income ex-interest (AUD K) | -3,360 | -7,850 | -5,230 | -10,736 | -6,584 |
EBITDA (AUD K) | -3,360 | -7,850 | -5,229 | -10,736 | -6,584 |
Pre-tax income (AUD K) | -3,362 | -7,792 | -5,069 | -10,599 | -6,539 |
Net income (AUD K) | -3,362 | -7,792 | -5,069 | -10,599 | -6,539 |
EPS basic (A$ cents) | — | — | — | -1.02 | -0.55 |
EPS diluted (A$ cents) | — | — | — | -1.02 | -0.55 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | 2,023 | 5,309 | 12,213 | 3,240 | 2,747 |
Cash and equivalents (AUD K) | 1,895 | 5,026 | 11,625 | 3,031 | 2,386 |
Short-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net debt (AUD K) | -1,895 | -5,026 | -11,625 | -3,031 | -2,386 |
Total liabilities (AUD K) | 593 | 1,347 | 315 | 286 | 2,136 |
Total equity (AUD K) | 1,430 | 3,962 | 11,899 | 2,955 | 611 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD K) | 1,430 | 3,962 | 11,898 | 2,955 | 611 |
Accumulated losses (AUD K) | — | — | -41,557 | -52,156 | -58,695 |
Contributed equity (AUD K) | — | — | 46,735 | 48,914 | 52,494 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | — | — | -4,600 | -9,024 | -4,224 |
Of which R&D tax refund received (AUD K) | — | — | — | 2,444 | 4,734 |
Capex (AUD K) | -3 | 0 | 0 | 0 | 0 |
Free cash flow (AUD K) | — | — | -4,600 | -9,024 | -4,224 |
Net financing cash flow (AUD K) | — | — | 11,200 | 430 | 3,580 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | -2,932 | 3,130 | 6,600 | -8,595 | -645 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (% on average equity) | -127 | -289 | -64 | -143 | -367 |
ROA (% on average assets) | -96 | -213 | -58 | -137 | -218 |
Current ratio (x) | 3.41 | 3.94 | 38.77 | 11.33 | 1.29 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Asset turnover (x) | 0.01 | 0 | 0 | 0 | 0 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia operating revenue (AUD K) | 0 | 0.2 | 0 |
Malta / Europe operating revenue (AUD K) | 0 | 0 | 0 |
Americas operating revenue (AUD K) | 0 | 0 | 0 |
Total operating revenue (AUD K) | 0 | 0.2 | 0 |
Share Price
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.053 | 0.07 | 0.04 | 0.07 | 0.015 |
Share Price & Returns
| Period (to late Aug 2026, approx. A$0.013) | Return (%) |
|---|---|
1 year (from A$0.015, Jun 2025) | -13 |
3 years (from A$0.04, Jun 2023) | -68 |
5 years (from A$0.053, Jun 2021) | -75 |
Capital Markets
| Measure | Value | Comment |
|---|---|---|
Market cap | ~A$21m | ~1.62bn shares × A$0.013 |
Enterprise value | ~A$15–19m (indicative) | Market cap less pro-forma cash (A$2.4m at 30 Jun plus ~A$4.2m net placement and A$3.15m loan proceeds, less loan) |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No sales |
P/B | ~34x on 30 Jun 2026 book (A$0.61m) | Book value depressed; pro-forma book after August raise is higher |
Capital Markets — Analyst consensus
| Item | Status |
|---|---|
Analyst consensus | None identified; no published broker coverage found |
Dividend history and policy | No dividends ever paid; none expected |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Capital structure overhang | 40m management options (strike A$0.10–0.18, out of the money); 19.5m adviser options (A$0.02–0.03); 22.5m proposed JLM options (A$0.02/0.035); up to 35m Fenix performance rights |
Index membership | Not in S&P/ASX indices; no ETF holders |
Analyst Conclusions
Management guidance. The company guides only that it expects the August 2026 placement plus existing cash to fund operations to topline Phase 3 data; no timing for topline, revenue or earnings guidance has been given. Consensus growth expectations: none (no coverage).
Bull case
-
HARMONY's statistically significant, peer-reviewed results across multiple validated scales, combined with a pivotal Phase 3 now dosing at six sites with strong recruitment demand, provide a credible path to the first approved therapy for ASD core symptoms.
-
Regulatory scaffolding is unusually well developed for a ~A$21m company: FDA IND, ODD and RPDD in Rett, EU orphan designation, clean GLP toxicology and US method patents to 2042 — assets that would be valued by a licensee.
-
The share register is priced for failure; a positive interim or topline readout, or a licence deal, would trigger re-rating mechanics already embedded in management and Fenix incentives (A$200–300m market cap hurdles, A$0.25–0.30 VWAP hurdles).
Bear case
-
ASD core-symptom trials have a poor industry record; a 54-patient Phase II/III result is a fragile foundation, and the change in planned enrolment from 150 to up to 200 hints at uncertainty about effect size.
-
The balance sheet is precarious: A$0.61m of net assets at June 2026, an audit going-concern emphasis and rising Phase 3 burn mean the "funded to topline" claim leaves little margin; further raises near A$0.014 would continue heavy dilution.
-
FDA may not accept Australian-only pivotal efficacy data or botanical manufacturing consistency without additional US studies, delaying the US value inflection on which a licensing deal would rest.
Key catalysts and monitorables (next 12 months)
Analyst verdict. Neurotech International is a binary, single-asset bet on whether a CBDA-rich, multi-cannabinoid extract can do what no approved drug does: measurably improve adaptive behaviour in children with moderate-to-severe autism. FY2026 marked a genuine transition. The company converted a decade of meandering — from a Maltese neurofeedback headset to cannabis strains to a cluster of small open-label studies — into a disciplined, registration-oriented programme with an FDA-cleared IND, orphan and rare-paediatric designations in Rett, GLP toxicology supporting chronic dosing, a peer-reviewed placebo-controlled dataset and, since 21 September 2026, a pivotal Phase 3 dosing across six Australian sites. Those are real assets, and at roughly A$21 million of market value the market is ascribing little to them.
The discount, however, is earned. The company ended FY2026 with A$2.4 million of cash, A$0.6 million of net assets, payables that had swollen nine-fold as Phase 3 costs accrued, and an auditor-flagged material uncertainty over going concern. Survival has relied on equity issued at 1.4 cents and on borrowing against future tax refunds; share count has risen by more than half in fourteen months. The board is small, now led by an executive chairman whose background is capital raising, and lacks the committee architecture that institutional investors expect. The scientific risk is material too: autism trials frequently fail, HARMONY enrolled only 54 children, and the planned Phase 3 size has already moved.
Our view: the investment case is a call option on Beyond Harmony topline data and on the company's ability to convert its regulatory package into a licensing transaction before the next funding gap. Appropriate monitorables are quarterly burn versus the "funded to topline" guidance, enrolment velocity, any adaptive-interim disclosures and the terms of any partnership. Position sizing should assume a meaningful probability of further dilution and a non-trivial probability of total loss, balanced against multi-bagger upside on clean Phase 3 success. Rating stance: speculative; suitable only for high-risk, event-driven biotech allocations.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Education | Interests (FY2026 AR) |
|---|---|---|---|---|---|
Mark Davies | Executive Chairman (from 17 Aug 2026); Non-Executive Chairman 15 Aug 2022–16 Aug 2026; service agreement from 27 May 2019 | Board since 2019 | 20+ years in trading, investment banking and corporate advice; Montagu Stockbrokers; co-founder of Cygnet Capital and later 1861 Capital; former Non-Executive Chairman of Tryptamine Therapeutics (ASX: TYP) | B.Com, University of Western Australia | 18,935,875 shares |
Dr Anthony Filippis | Managing Director and CEO | Since 1 Feb 2025 | 25+ years across biotech, healthcare and investment; neuroscience, oncology and endocrinology; senior roles at ASX-listed and private life-science companies; licensing and M&A experience; NED of VivaZome Therapeutics and Connectivity Limited | PhD Biochemistry; MBA | 3,571,428 shares; 20m options ($0.16/$0.18, expiring 24 Feb 2030) |
Robert (Max) Johnston | Non-Executive Director | Since 19 Apr 2024 | 11 years as President and CEO of Johnson & Johnson Pacific; senior roles at Unilever and Guinness-United Distillers; past President of ACCORD Australasia, Vice Chair of AFGC, ASMI board; NED of Inoviq (ASX: IIQ) | — | 4,604,761 shares |
Gerald Quigley | Non-Executive Director and Director of Public Relations | Since 7 Jul 2022 | Pharmacist and national media health commentator; experience in pharmaceutical/nutraceutical development and TGA/FDA positioning | B.Pharm | 3,849,205 shares |
Alessandra Gauvin | Company Secretary | — | 8+ years company secretarial experience with ASX-listed companies | B.Com (Accounting and Business Law); Grad. Dip. Applied Corporate Governance; Chartered Secretary | — |
Prof. Michael Fahey | Principal Investigator, Beyond Harmony; manages AP program | Long-standing | Paediatric neurologist, Monash | — | Not a KMP |
“—” = not publicly disclosed.
Directors' Remuneration
| KMP | Salary/fees | Superannuation | Annual leave | Options (SBP) | Total | Performance-related % |
|---|---|---|---|---|---|---|
Mark Davies | 100,000 | 0 | 0 | 0 | 100,000 | 0 |
Robert Johnston | 50,000 | 0 | 0 | 0 | 50,000 | 0 |
Gerald Quigley | 50,000 | 0 | 0 | 0 | 50,000 | 0 |
Anthony Filippis | 420,000 | 50,400 | 14,016 | 128,883 | 613,299 | 21 |
Total | 620,000 | 50,400 | 14,016 | 128,883 | 813,299 | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
26 Jul 2024 | Dr Alexandra Andrews ceases employment (received A$60,000 termination benefit) | Management restructuring |
1 Feb 2025 | Dr Anthony Filippis appointed MD/CEO | Shift toward late-stage development and partnering |
1 Apr 2025 | Thomas Duthy (Executive Director) resigns | Board streamlining |
17 Aug 2026 | Mark Davies becomes Executive Chairman | Focus on funding, partnering/licensing and capital markets during Phase 3 |
Major Shareholders
| Holder (top 10 not fully disclosed) | Shares | % |
|---|---|---|
The Trust Company (Australia) Limited <MOF A/C> | 30,506,500 | 2.91 |
Mark Davies (director, indirect) | 18,935,875 | 1.17 |
Robert Johnston (director) | 4,604,761 | 0.28 |
Gerald Quigley (director) | 3,849,205 | 0.24 |
Anthony Filippis (director) | 3,571,428 | 0.22 |
Competitive Landscape
Key Competitors
| Company | Area of overlap | Asset | Status | Relative positioning vs NTI |
|---|---|---|---|---|
Jazz Pharmaceuticals (Nasdaq: JAZZ) | Cannabinoid neurology | Epidiolex (purified CBD) | Approved for Dravet, Lennox-Gastaut, TSC seizures; ~US$0.9–1.0bn annual sales (approx.) | Validates cannabinoid medicines; prescribers may use off-label in ASD; massive scale advantage |
Acadia Pharmaceuticals (Nasdaq: ACAD) | Rett syndrome | Daybue (trofinetide) | FDA-approved 2023; several hundred US$m annual sales (approx.) | Incumbent Rett standard; NTI would need differentiated tolerability (Daybue has GI side-effects) |
Neuren Pharmaceuticals (ASX: NEU) | Rett, neurodevelopmental | Trofinetide royalties; NNZ-2591 | Royalty-funded; Phase 2/3 programmes | ASX peer in paediatric neurodevelopment; far larger market cap |
Harmony Biosciences (Nasdaq: HRMY) via Zynerba | Cannabinoid, neurodevelopmental | Zygel (transdermal CBD) for Fragile X / ASD-adjacent | Late-stage (status should be checked) | Direct cannabinoid-in-neurodevelopment comparator with big-company backing |
Otsuka / BMS (aripiprazole); J&J (risperidone) | ASD irritability | Atypical antipsychotics | Approved for irritability, not core symptoms | Standard of care NTI aims to complement or displace on tolerability |
Roche | ASD core symptoms | Balovaptan | Discontinued after Phase 3 | Illustrates high failure rate in ASD core-symptom trials |
Curemark | ASD | CM-AT (enzyme) | Late-stage/regulatory (status uncertain) | Alternative non-psychotropic approach |
Axial Therapeutics | ASD (gut-brain) | AB-2004 | Clinical stage | Mechanistic competitor in ASD irritability |
Bod Science / Zelira Therapeutics / Incannex (ASX/Nasdaq) | Medicinal cannabis R&D | Various cannabinoid formulations | Clinical/early commercial | Compete for investor capital and clinician mind-share in Australian cannabinoid medicine |
Australian medicinal cannabis suppliers (prescribed under SAS/AP) | Unregistered cannabinoid products | CBD oils | Widely prescribed | Low-cost "grey" competition; NTI's registration would be a differentiator |
Peer Comparison FY2026
| Metric | Neurotech (FY2026) | Neuren (approx.) | Acadia (approx.) | Jazz (approx.) |
|---|---|---|---|---|
Revenue | ~A$0 | Royalty/milestone income in the A$ tens to hundreds of millions | Hundreds of US$m (total company ~US$1bn) | ~US$4bn total company |
Revenue growth | n/m | Volatile (milestones) | Positive | Low single digit |
Profitability | Net loss A$6.5m | Profitable in milestone years | Near break-even/profitable | Profitable |
R&D intensity | ~79% of expenses | High | ~20–30% of revenue | ~20% of revenue |
Recent Developments
Litigation, regulatory enforcement, layoffs or guidance revisions: none identified.



